A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
NCT02998476
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
Parsaclisib
Sponsor
Incyte Corporation